Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
URMC / Research / Clinical Trials / Study Details

Lymphoma (Bone Marrow Transplant): Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Research Question:
What are the good and/or bad effects of using an oral medication, ibrutinib, along with the autologous hematopoietic stem cell transplantation (AutoHCT) versus AutoHCT alone?

Basic Study Information

This study has two treatment groups: Group 1: For the first 6 days, you will get the usual chemotherapy (BEAM or CBV), plus the study drug ibrutinib. Then, you will receive ibrutinib for 12 months following AutoHCT. Group 2: For the first 6 days, you will get the usual chemotherapy (BEAM or CBV), plus a placebo (a pill that looks like the study drug but contains no medication). Then, you will receive a placebo for 12 months following AutoHCT. However, if you were to progress or relapse while taking the placebo, you would be offered treatment with the study drug, ibrutinib, at that time. The researchers want to know if adding ibrutinib to the usual chemotherapy given with AutoHCT could prevent your lymphoma from returning in the future. However, the addition of this medication could also cause side effects that the researchers want to know about.

Location: Cancer Center
Study Web URL:
Study Reference #: CBMT17006

Lead Researcher (Principal Investigator)

Lead Researcher: Michael Becker, MD

Study Contact Information

Study Coordinator: Robin Boerman
Phone: (585) 273-1507

Additional Study Details

Return to Search